Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pérez Holanda, Sergio ^a   Blanco, Ignacio ^b   Menéndez, Manuel ^c   Rodrigo, Luis ^c  

^a HOSPITAL VALLE DEL NALÓN   (Spain)

^b Board of Directors of the Alpha 1 Antitrypsin Deficiency Spanish Registry Lung Foundation Breathe Spanish Society of Pneumology (SEPAR)   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Alpha 1 antitrypsin; Colorectal cancer; Gene frequency; Serum concentration

Indexed keywords

ALPHA 1 ANTITRYPSIN; SERPINA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OUTCOME ASSESSMENT; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SPAIN; VERY ELDERLY; ALPHA 1-ANTITRYPSIN DEFICIENCY; BLOOD; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS; GENOTYPE; MIDDLE AGED; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; SPAIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84901475149     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-355     Document Type: Article

References (62)

1. American Thoracic Society/ European Respiratory Society Statement Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003, 168:818-900. American Thoracic Society/ European Respiratory Society Statement.
2. Lomas DA. Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency. COPD 2013, 10(Suppl 1):17-25.
3. Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012, 185:246-259. 10.1164/rccm.201108-1428CI, 21960536.
4. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005, 42:514-521. 10.1002/hep.20815, 16044402.
5. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998, 22:742-748. 10.1097/00000478-199806000-00012, 9630182.
6. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008, 168:1097-1103. 10.1001/archinte.168.10.1097, 2562773, 18504338.
7. Yang P, Wentzlaff KA, Katzmann JA, Marks RS, Allen MS, Lesnick TG, Lindor NM, Myers JL, Wiegert E, Midthun DE, Thibodeau SN, Krowka MJ. Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999, 8:461-465.
8. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004, 5:182-190. 10.1016/S1470-2045(04)01414-7, 15003202.
9. Yang P, Bamlet WR, Sun Z, Ebbert JO, Aubry MC, Krowka MJ, Taylor WR, Marks RS, Deschamps C, Swensen SJ, Wieben ED, Cunningham JM, Melton LJ, de Andrade M. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005, 128:445-452. 10.1378/chest.128.1.445, 16002971.
10. Benkmann HG, Hanssen HP, Ovenbeck R, Goedde HW. Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered 1987, 37:290-293. 10.1159/000153720, 3499374.
11. Callea F, Stuyck JM, Massi G, Huyghe JD, Van Gijsegem DF, Jadoul DH, Desmet VJ. Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). Am J Clin Pathol 1982, 78:878-883.
12. Callea F, Massi G, De Wolf-Peeters C, Lievens C, Desmet VJ. Alpha-1-antitrypsin phenotypes in malignant lymphoma. J Clin Pathol 1982, 35:1213-1215. 10.1136/jcp.35.11.1213, 497929, 6982905.
13. Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiegert EM, Christensen ER, Lindor NM, Katzmann JA, Thibodeau SN. Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 2000, 71:639-645. 10.1006/mgme.2000.3089, 11136557.
14. Lindor NM, Yang P, Evans I, Schowalter K, De Andrade M, Li J, Jeavons E, Peterson G, Gallinger S, Bapat B, Hopper J, Jass J, Jenkins M, Templeton A, Potter J, Newcomb PA, Lemarchand L, Grove J, Haile R, Baron J, Seminara D, Limburg P, Thibodeau SN. Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab 2010, 99:157-159. 10.1016/j.ymgme.2009.09.010, 2818220, 19853488.
15. Blanco I, Fernández E, Rodríguez MC, Fernández A. Allelic frequency of the gene of alpha-1-antitrypsin in the general population in a county in Asturias. Med Clin (Barc) 1999, 113:366-370.
16. Blanco I, Fernández E. Alpha1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. Respir Med 2001, 95:109-114. 10.1053/rmed.2000.0964, 11217906.
17. Pérez-Holanda S, Rodrigo L, Pinyol-Felis C, Vinyas-Salas J. Colonic perianastomotic carcinogenesis in an experimental model. BMC Cancer 2008, 8:217. 10.1186/1471-2407-8-217, 2518563, 18667092.
18. Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ. National comprehensive cancer network. Colon cancer clinical practice guidelines in oncology. Natl Compr Canc Netw 2005, 3:468-491.
19. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain. Clin Genet 2003, 63:490-509. 10.1034/j.1399-0004.2003.00078.x, 12786756.
20. Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006, 27:77-84. 10.1183/09031936.06.00062305, 16387939.
21. Ward AM, Cooper EH, Turner R, Anderson JA, Neville AM. Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes. Br J Cancer 1977, 35:170-178. 10.1038/bjc.1977.24, 2025326, 13805.
22. Bernacka K, Kurryliszyn-Moskal A, Sierakowski S. The levels of alpha 1-antitrypsin and alpha 1-antichymotrypsin in the sera of patients with gastrointestinal cancer during diagnosis. Cancer 1988, 62:1188-1193. 10.1002/1097-0142(19880915)62:6<1188::AID-CNCR2820620624>3.0.CO;2-E, 3261623.
23. Stamatiadis AP, Toumanidou MS, Vyssoulis GP, Mnouras AJ, Apostolidis NS. Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer. Cancer 1990, 65:2055-2057. 10.1002/1097-0142(19900501)65:9<2055::AID-CNCR2820650927>3.0.CO;2-6, 1695546.
24. Bujanda L, Sarasqueta C, Cosme A, Hijona E, Enríquez-Navascués JM, Placer C, Villarreal E, Herreros-Villanueva M, Giraldez MD, Gironella M, Balaguer F, Castells A. Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer. PLoS One 2013, 8:e51810. 10.1371/journal.pone.0051810, 3534697, 23300952.
25. Harris CC, Cohen MH, Connor R, Primack A, Saccomanno G, Talamo RC. Serum alpha1-antitrypsin in patients with lung cancer or abnormal sputum cytology. Cancer 1976, 38:1655-1657. 10.1002/1097-0142(197610)38:4<1655::AID-CNCR2820380435>3.0.CO;2-F, 1086707.
26. Daddi G, Mancini PA, Parola D, Matzeu M. Behaviour of alpha1-antitrypsin in lung cancer. Scand J Respir Dis Suppl 1978, 102:205-206.
27. Hansen JE, Iversen J, Lihme A, Bøg-Hansen TC. Acute phase reaction, heterogeneity, and microheterogeneity of serum proteins as nonspecific tumor markers in lung cancer. Cancer 1987, 60:1630-1635. 10.1002/1097-0142(19871001)60:7<1630::AID-CNCR2820600735>3.0.CO;2-X, 2441848.
28. Ferrigno D, Buccheri G, Camilla T. Prognosis and lung-cancer - the contribution of plasma-proteins. Oncol Rep 1995, 2:637-641.
29. Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, Mandrekar SJ, Yang P. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. J Thorac Oncol 2011, 6:291-295. 10.1097/JTO.0b013e31820213fb, 3927968, 21173712.
30. Topic A, Ljujic M, Petrovic-Stanojevic N, Dopudja-Pantic V, Radojkovic D. Phenotypes and serum level of alpha-1-antitrypsin in lung cancer. J BUON 2011, 16:672-676.
31. Sekine C, Aoyagi Y, Suzuki Y, Ichida F. The reactivity of alpha-1-antitrypsin with Lens culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver. Br J Cancer 1987, 56:371-375. 10.1038/bjc.1987.205, 2002189, 2822074.
32. Dabrowska M, Mantur M, Panasiuk A, Prokopowicz J. Does the concentration of alpha 1-proteinase inhibitor reflect the transformation of liver cirrhosis to liver carcinoma?. Neoplasma 1997, 44:305-307.
33. Tountas Y, Sparos L, Theodoropoulos C, Trichopoulos D. Alpha 1-antitrypsin and cancer of the pancreas. Digestion 1985, 31:37-40. 10.1159/000199175, 3872237.
34. Ward AM, Cooper EH, Houghton AL. Acute phase reactant proteins in prostatic cancer. Br J Urol 1977, 49:411-418. 10.1111/j.1464-410X.1977.tb04168.x, 73395.
35. Latner AL, Turner GA, Lamin MM. Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix. Oncology 1976, 33:12-14. 10.1159/000225093, 1086450.
36. Zbroja-Sontag W. Defense proteins and immune complexes in the blood serum of women with inflammatory and neoplastic lesions of the ovary. Am J Reprod Immunol 1983, 4:11-20. 10.1111/j.1600-0897.1983.tb00247.x, 6194700.
37. Warwas M, Gerber J, Pietkiewicz A. Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary. Neoplasma 1986, 33:79-84.
38. Vasishta A, Baker PR, Preece PE, Wood RA, Cuschieri A. Serum proteinase-like peptidase activities and proteinase inhibitors in women with breast disease. Eur J Cancer Clin Oncol 1984, 20:197-202. 10.1016/0277-5379(84)90184-6, 6200326.
39. Dabrowska M, Kemona H, Prokopowicz J, Kiluk S. Serum concentration of alpha-2-macroglobulin, alpha-1-antitrypsin and alpha-1-antichymotrypsin in patients with Hodgkin's disease. Mater Med Pol 1992, 24:28-30.
40. Krecicki T, Leluk M. Acute phase reactant proteins-an aid to monitoring surgical treatment of laryngeal carcinoma. J Laryngol Otol 1992, 106:613-615. 10.1017/S002221510012033X, 1382109.
41. Brkic S, Salkic A, Nuhbegovic S, Brkic F, Umihanic S. Influence of surgical therapy on serum values of alpha 1-antitrypsin in patients with head and neck tumors. Med Arh 2011, 65:99-101.
42. Karashima S, Kataoka H, Itoh H, Maruyama R, Koono M. Prognostic significance of a-1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer 1990, 45:244-250. 10.1002/ijc.2910450207, 2303291.
43. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of a-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer 1992, 65:300-302. 10.1038/bjc.1992.60, 1977730, 1739634.
44. Glasgow JE, Bagdasarian A, Colman RW. Functional alpha 1 protease inhibitor produced by a human hepatoma cell line. J Lab Clin Med 1982, 99:108-117.
45. Kittas C, Aroni K, Kotsis L, Papadimitriou CS. Distribution of lysozyme, alpha 1-antichymotrypsin and alpha 1-antitrypsin in adenocarcinomas of the stomach and large intestine. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1982, 398:139-147. 10.1007/BF00618865, 6819707.
46. Tahara E, Ito H, Taniyama K, Yokozaki H, Hata J. Alpha 1-antitrypsin, alpha 1-antichymotrypsin, and alpha 2-macroglobulin in human gastric carcinomas: a retrospective immunohistochemical study. Hum Pathol 1984, 15:957-964. 10.1016/S0046-8177(84)80125-2, 6207098.
47. Krugliak L, Meyer PR, Taylor CR. The distribution of lysozyme, alpha-1-antitrypsin, and alpha-1-antichymotrypsin in normal hematopoietic cells and in myeloid leukemias: an immunoperoxidase study on cytocentrifuge preparations, smears, and paraffin sections. Am J Hematol 1986, 21:99-109. 10.1002/ajh.2830210112, 3518416.
48. Meyer PR, Krugliak L, Neely S, Levine A, Parker JW, Kaplan B, Taylor CR. Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic alpha-1-anti-chymotrypsin and alpha-1-anti-trypsin as possible indicators of early granulocytic differentiation. Am J Clin Pathol 1986, 86:461-468.
49. Sawaya R, Zuccarello M, Highsmith R. Alpha-1-antitrypsin in human brain tumors. J Neurosurg 1987, 67:258-262. 10.3171/jns.1987.67.2.0258, 3496430.
50. Soini Y, Miettinen M. Alpha-1-antitrypsin and lysozyme. Their limited significance in fibrohistiocytic tumors. Am J Clin Pathol 1989, 9:515-521.
51. Kataoka H, Nabeshima K, Komada N, Koono M. New human colorectal carcinoma cell lines that secrete proteinase inhibitors in vitro. Virchows Arch B Cell Pathol 1989, 57:157-165.
52. Kataoka H, Seguchi K, Inoue T, Koono M. Properties of a1-antitrypsin secreted by human adenocarcinoma cell lines. FEBS Lett 1993, 328:291-295. 10.1016/0014-5793(93)80946-R, 8348978.
53. Xie LQ, Zhao C, Cai SJ, Xu Y, Huang LY, Bian JS, Shen CP, Lu HJ, Yang PY. Novel proteomic strategy reveals combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010, 9:4701-4709. 10.1021/pr100406z, 20666480.
54. Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS, Lee SC, Wang WM. Discovery of tumor markers for gastric cancer by proteomics. PLoS One 2014, 9:e84158. 10.1371/journal.pone.0084158, 3880290, 24404153.
55. Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV. Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 2004, 112:1042-1048. 10.1002/ijc.20494, 15316942.
56. Keppler D, Markert M, Carnal B, Berdoz J, Bamat J, Sordat B. Human colon carcinoma cells synthesize and secrete alpha 1-proteinase inhibitor. Biol Chem Hoppe Seyler 1996, 377:301-311. 10.1515/bchm3.1996.377.5.301, 8828821.
57. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001, 189:197-206. 10.1002/jcp.10014, 11598905.
58. Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol 1999, 154:457-468. 10.1016/S0002-9440(10)65292-3, 1849991, 10027404.
59. Perlmutter DH, Daniels JD, Auerbach HS, De Schryver-Kecskemeti K, Winter HS, Alpers DH. The alpha 1-antitrypsin gene is expressed in a human intestinal epithelial cell line. J Biol Chem 1989, 264:9485-9490.
60. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG, Khatib AM. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 2008, 118:352-363. 10.1172/JCI32040, 2117762, 18064302.
61. Nejjari M, Berthet V, Rigot V, Laforest S, Jacquier MF, Seidah NG, Remy L, Bruyneel E, Scoazec JY, Marvaldi J, Luis J. Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model. Am J Pathol 2004, 164:1925-1933. 10.1016/S0002-9440(10)63753-4, 1615749, 15161629.
62. Khatib AM, Siegfried G, Prat A, Luis J, Chrétien M, Metrakos P, Seidah NG. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 2001, 276:30686-30693. 10.1074/jbc.M101725200, 11402025.